14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MDCX vs VENU: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Medicus Pharma Ltd. (MDCX) captures the overall head-to-head institutional edge over Venu Holding Corporation (VENU) on higher Unified Composite conviction (49.2/100 HOLD vs. 42.3/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while VENU wins 3–2 across the 6-pillar growth and valuation breakdown. MDCX trades at $1.14 (N/M Forward P/E, 0.0% operating margin) versus VENU at $0.99 (N/M Forward P/E, -294.7% operating margin).
Growth vs. Quality Trade-Off: MDCX earns the overall head-to-head edge with a stronger Unified Composite Score (49.2/100 HOLD vs. VENU 42.3/100 HOLD) and -0.28β · 118% Vol risk profile, whereas VENU leads top-line expansion (+2.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: MDCX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 36.1); meanwhile VENU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MDCX vs VENU. Trailing 12-month operating profitability (MDCX 0.0% vs VENU -294.7%) and valuation multiples (MDCX N/M vs VENU N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Restaurants value chain with $58.3M market capitalization and -294.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MDCX vs VENU Key Questions & Quantitative Answers
As of Nov 20, 2026, Medicus Pharma Ltd. (MDCX) captures the overall head-to-head institutional edge over Venu Holding Corporation (VENU) on higher Unified Composite conviction (49.2/100 HOLD vs. 42.3/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while VENU wins 3–2 across the 6-pillar growth and valuation breakdown. MDCX trades at $1.14 (N/M Forward P/E, 0.0% operating margin) versus VENU at $0.99 (N/M Forward P/E, -294.7% operating margin). Growth vs. Quality Trade-Off: MDCX earns the overall head-to-head edge with a stronger Unified Composite Score (49.2/100 HOLD vs. VENU 42.3/100 HOLD) and -0.28β · 118% Vol risk profile, whereas VENU leads top-line expansion (+2.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MDCX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 36.1); meanwhile VENU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VENU leads the Growth & Scale pillar: MDCX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VENU at +2.9% YoY revenue growth and +0.0% YoY earnings growth on $19M TTM revenue (16.4% gross margin, -294.7% operating margin). On trailing 12-month operating scale, MDCX generates N/A in USD-normalized revenue versus $19M for VENU. In operating R&D and SG&A reinvestment, MDCX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VENU.
VENU screens cheaper on headline valuation multiples. MDCX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas VENU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 12.1x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MDCX (-7446.1% ROE) versus VENU (-24.9% ROE) capital efficiency.
In options market volatility and institutional positioning, MDCX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.28β · 118% Vol realized risk). By comparison, VENU carries 76.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.72β · 86% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.